TMED9 and cancer: Copy number variation analysis similarly revealed that TMED9 had a greater number of amplification mutations in various cancers, including adrenocortical carcinoma (ACC) and KIRC, while an increased incidence of deletion mutations was observed in bladder urothelial carcinoma (BLCA), lung squamous cell carcinoma (LUSC), and testicular germ cell tumors (TGCT) (Figure 2C).